Company: DMAAR
Filing Date: 2025-01-22
Form Type: POS AM
Source: 0001213900-25-005176
Chunk: 198

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-01-22
Form: POS AM
Chunk 198
---
 $10.00 per unit ($500,000 in the aggregate); subject to each non -managingsponsor investor purchasing, through the sponsor, the private placement units allocated to it in connection with the closing of this offering, the sponsor will issue membership interests at a nominal purchase price to the non -managingsponsor investors at the closing of this offering reflecting interests in an aggregate of 666,667 founder shares held by sponsor. The non -managingsponsor investors are not granted any shareholder or other rights in addition to those afforded to our other public shareholders, and will only be issued membership interests in the sponsor, with no right to control the sponsor or vote or dispose of any securities held by the sponsor, including the founder shares held by the sponsor. Immediately after this offering, our initial shareholders will beneficially own 30% of the then issued and outstanding ordinary shares (not including the private units and the representative shares and assuming our initial shareholders do not purchase any units in this offering). In addition, because of their ownership block, our initial shareholders may be able to effectively influence the outcome of all other matters requiring approval by our shareholders, including amendments to our amended and restated memorandum and articles of association and approval of significant corporate transactions.

127

SPONSOR OWNERSHIP Drugs Made In America Acquisition LLC is our sponsor. Formed in April 2024, the sponsor is a U.S. -basedlimited liability company formed for the purpose of acting as the sponsor in connection with this offering and the sponsor conducts no other business. The managing member of the sponsor is Lynn Stockwell, our Chief Executive Officer and Executive Chair. Ms. Stockwell controls the management of our sponsor, including the exercise of voting and investment discretion over the securities of our company held by our sponsor. As of the date of this prospectus, Ms. Stockwell owns membership interests in our sponsor, which represent 100% of the economic interests in our sponsor. Additionally, subject to each non -managingsponsor investor purchasing, through the sponsor, the private units allocated to it in connection with the closing of this offering, the sponsor will issue membership interests at a nominal purchase price to the non -managingsponsor investors reflecting interests in an aggregate of 666,667 founder shares held by the sponsor. Non -managingsponsor investors will have no right to control the sponsor or participate in any decision regarding the disposal of any security held by the sponsor, or otherwise. As of the date hereof, other than Ms. Stockwell, no